ABSTRACT
Lutetium-177 (Lu-177) is being widely used in nuclear medicine due to its physical properties suitable for therapy and imaging. In this review production methods, fundamental chemistry and common radiopharmaceuticals of Lu-177 is presented. As research on Lu-177 radiopharmaceuticals expand; it is predicted that availability of Lu-177 will increase and new Lu-177 radiopharmaceuticals will go through regulatory steps to be registered and made available for patient use.
References
1“Lutetium.” Chemicool Periodic Table. Chemicool.com. 17 Oct. 2012 https://www.chemicool.com/elements/lutetium.html.
2“Lutetium”Pubchem- https://pubchem.ncbi.nlm.nih.gov/compound/71587001.
3Nuclide Safety Data Sheet Lutetium-177 www.nchps.org.
4Dash A, Pillai MR, Knapp FF Jr. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nucl Med Mol Imaging 2015;49:85-107.
5Chakravarty R, Chakraborty S. A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route. Am J Nucl Med Mol Imaging 2021;11:443-475.
6Gersman J, Kleehammer D, Letteri R, Dillehay G. Radiation safety evaluation for Lu177 therapies in the outpatient hospital setting. J Nucl Med 2020;61(Suppl 1):3023.
7Webb C, Frye S, Muzaffar R, Osman M. Radiation safety challenges in Lu-177 PSMA: A technologist’s prospective. J Nucl Med 2020;61(Suppl 1):3035.
8Konijnenberg MW. Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry. Curr Radiopharm 2015;8:145-149.
9Banerjee S, Pillai MR, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev 2015;115:2934-2974.
10Gleisner KS, Brolin G, Sundlöv A, et al. Long-Term Retention of 177Lu/177mLu-DOTATATE in Patients Investigated by γ-Spectrometry and γ-Camera Imaging. J Nucl Med 2015;56:976-984.
11Müller WA, Linzner U, Schäffer EH. Organ distribution studies of lutetium-177 in mouse. Int J Nucl Med Biol 1978;5:29-31.
12Lutetium (Lu-177) Solution for Radiolabelling 07/2017/2798 European Pharmacopoeia; 9.2- s.4436.
13Hashimoto K, Matsuoka H, Uchida S. Production of nocarrier-added 177Lu via the 176Yb (n, γ) 177Yb→177Lu process. J Radioanal Nucl Chem 2003;255:575-579.
14Horwitz EP, McAlister DR, Bond AH, Barrans RE, Williamson JM. A process for the separation of 177Lu from neutron irradiated 176Yb targets. Appl Radiat Isot 2005;63:23-36.
15Lebedev NA, Novgorodov AF, Misiak R, Brockmann J, Rösch F. Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,gamma)177Yb-->177Lu process. Appl Radiat Isot 2000;53:421-425.
16Marx S, Harfensteller M, Zhernosekov K and Nikula T. Method of manufacturing non carrier added high purity 177Lu compounds as well as non-carrier added 177Lu compounds. U.S. Patent. US 2014/0294700 A1.
17Park H, Kwon D, Cha Y, et al. Laser isotope separation of 176Yb for medical applications. J Korean Phys Soc 2006;49:382-386.
18Knapp FF. Lutetium-177 - Broad production capabilities are expected to stimulate clinical applications of this important therapeutic radioisotope. International Atomic Energy Agency (IAEA), Technical Meeting on Therapeutic Radiopharmaceuticals; 2010.
19Dash A, Chakravarty R, Knapp FF Jr, Pillai AM. Indirect Production of No Carrier Added (NCA) (177)Lu from Irradiation of Enriched (176)Yb: Options for Ytterbium/Lutetium Separation. Curr Radiopharm 2015;8:107-118.
20IUPAC. Compendium of Chemical Terminology, 2nd ed. Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). XML on-line corrected version: http://goldbook.iupac.org (2006).
21Le VS. Specific radioactivity of neutron induced radioisotopes: assessment methods and application for medically useful 177Lu production as a case. Molecules 2011;16:818-846.
22Breeman WA, de Zanger RM, Chan HS, de Blois E. Alternative method to determine Specific Activity of (177)Lu by HPLC. Curr Radiopharm 2015;8:119-122.
23Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917-920.
24Kwekkeboom DJ, Bakker WH, Kooij PPM, et al. [177Lu-DOTA0, Tyr3] octreotate: comparison with [111In-DTPA0] octreotide in patients. Eur J Nucl Med 2001;28:1319-1325.
25Kang KWA, Song YSB, Kwon TEC, Ha WHC, Jin YWC. Accidental injection of unlabeled Lu-177 caused catastrophic consequences in patients with neuroendocrine tumor. 17th Annual ENETS Conference, Abstract #2838, 2020.
26Chakraborty S, Vimalnath KV, Sharad PL, et al. On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience. J Radioanal Nucl Chem 2014;302:233-243.
27Guidelines on the Limits of Genotoxic Impurities (EMA / CHMP / SWP431994 / 2007 Rev.3).
28Trindade V, Balter H. Oxidant and Antioxidant Effects of Gentisic Acid in a 177Lu-Labelled Methionine-Containing Minigastrin Analogue. Curr Radiopharm 2020;13:107-119.
29Zanger RMS, Chan HS, Breeman WAP, de Blois E. Maintaining radiochemical purity of [177Lu]Lu‑DOTA‑PSMA‑617 for PRRT by reducing radiolysis. J Radioanal Nucl Chem 2019;321:285-291.
30Jamous M, Haberkorn U, Mier W. Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases. Molecules 2013;18:3379-3409.
31Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011;41:314-321.
32Breeman WA, Chan HS, de Zanger RM, Konijnenberg MK, de Blois E. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT. Curr Radiopharm 2016;9:8-18.
33Parus JL, Pawlak D, Mikolajczak R, Duatti A. Chemistry and bifunctional chelating agents for binding (177)Lu. Curr Radiopharm 2015;8:86-94.
34Rangger C, Haubner R. Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology. Pharmaceuticals (Basel) 2020;13:22.
35Mulligan T, Carrasquillo JA, Chung Y, et al. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1995;1:1447-1454.
36De Jong M, Breeman WA, Bernard BF, et al. [177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92:628-633.
37Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3] octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-422.
38Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124-2130.
39LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use. Prescribing Information. Advanced Accelerator Applications. Initial U.S. 2018.
40Hennrich U, Kopka K. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals (Basel) 2019;12:114.
41Kam BLR, DJ Kwekkeboom DJ. Peptide receptor radionuclide therapy using 177Lu Octreotide-Dutch Guideline PART II. 2013;439-443.
42Shah MH, Goldner WS, Halfdanarson TR, et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw 2018;16:693-702.
43Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800-816.
44Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci 2017;64:52-60.
45Kelly JM, Amor-Coarasa A, Nikolopoulou A, et al. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3. Nucl Med Biol 201;55:38-46.
46Lütje S, Heskamp S, Cornelissen AS, et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015;5:1388-1401.
47Kopka K. A short history of transforming the diagnostic tracer PSMA-11 into the theranostic variant PSMA-617. 4th Theranostics World Congress. Endocrine Abstracts 2016;47 OC29.
48Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med 2016;57:1006-1113.
49Heck MM, Retz M, D'Alessandria C, et al. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J Urol 2016;196:382-391.
50Hartrampf PE, Weinzierl FX, Buck AK, et al. Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2022;49:3269-3276.
51Donin NM, Reiter RE. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 2018;59:177-182.
52Gafita A, Heck MM, Rauscher I, et al. Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2020;61:1476-1483.
53Violet J, Sandhu S, Iravani A, et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2020;61:857-865.
54Mader N, Nguyen Ngoc C, Kirkgöze B, et al. Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2023;27.
55Mirshahvalad SA, Farzanefar S, Abbasi M. Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study. Asia Ocean J Nucl Med Biol 2023;11:23-29.
56Pluvicto (Lu-177 vipivotide tetraxetan) injection for intravenous use. Prescribing Information. Advanced Accelerator Applications USA; 2022.
57Araz M, Akkuş P. Radionuclide methods for pain palliation. Nucl Med Semin 2020;6:20-27.
58Bahrami-Samani A, Anvari A, Jalilian AR, et al. Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy Trials. Iran J Pharm Res 2012;11:137-144.
59Yuan J, Liu C, Liu X, et al. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med 2013;38:88-92.
60Agarwal KK, Singla S, Arora G, Bal C. (177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging 2015;42:79-88.
61Shinto AS, Shibu D, Kamaleshwaran KK, et al. ¹⁷⁷Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J Nucl Med Technol 2014;42:55-61.
62Sharma S, Singh B, Koul A, Mittal BR. Comparative Therapeutic Efficacy of 153Sm-EDTMP and 177Lu-EDTMP for Bone Pain Palliation in Patients with Skeletal Metastases: Patients' Pain Score Analysis and Personalized Dosimetry. Front Med (Lausanne) 2017;4:46.
63Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot 2008;66:1196-1205.
64Salek N, Shirvani Arani S, Bahrami Samani A, Vosoghi S, Mehrabi M. Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP. Australas Phys Eng Sci Med 2018;41:69-79.
65TAEK. Radyonüklit Tedavisi Gören Hastaların Taburcu Edilmesine İlişkin Kılavuz (RSGD-KLV-009/Rev-2); 2018.
66Calais PJ, Turner JH. Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors. Ann Nucl Med 2014;28:531-539.
67Demir M, Abuqbeitah M, Uslu-Beşli L, et al. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot 2016;36:269-278.
68Levart D, Kalogianni E, Corcoran B, Mulholland N, Vivian G. Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. EJNMMI Phys 2019;6:7.
69Kendi AT, Mailman JA, Naraev BG, Mercer DJ, Underwood JK, Halfdanarson TR. Patient Travel Concerns After Treatment with 177Lu-DOTATATE. J Nucl Med 2020;61:496-497.
